CART123 Cells therapy(Novartis Pharma)

N/A

Report date: 2025/01/13 20:00:48

Base Information

Drug NameCART123 Cells therapy(Novartis Pharma)
Drug Alias NameCART123
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of PennsylvaniaNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgUniversity Of Pennsylvania
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A